Dear All, MyCARE, a fungal patient advocacy organization, and the Partnership to Fight Infectious Diseases (PFID), are sending a letter to the California Congressional Delegation asking them to weigh in U.S. House and Senate leadership to pass the PASTEUR Act by the end of the year. The state of California has the largest Congressional delegation and
Dear All, Anthony McDonnell and his colleagues at CGD (Center for Global Development) have just released a truly lovely paper on the economics of antibiotic resistance. What makes this one special is that the paper dissects the problem of AMR through an economist’s spectacles in a way that is very accessible to the non-expert. You
Dear All, A new paper from Anthony McDonnell and a team led by the Center for Global Development extends estimates of the health-related impact of AMR (e.g., death) to a consideration of the economic ($) cost of AMR. To follow the plot, here are the links you will need: The new paper: “Forecasting the Fallout
Dear All, Four big reports have recently been released and are very much worth reviewing. First, the Global AMR R&D Hub and the WHO AMR Team have written a report entitled “Incentivising the development of new antibacterial treatments“. This report is a response to a 2021 request by the G7 Finance Ministers for a report on
Dear All (and with thanks to Damiano for co-authoring), We have exciting news from the G7 Health Ministers’ Meeting, which was held in person in Ancona on 9-11 October 2024, and the accompanying G7 Joint Finance and Health Ministers’ Meeting, which took place in a hybrid format on 10 October 2024. At the press conference closing
Dear All (and with thanks to Kevin for co-authoring and also a wonkish alert … get your coffee and settle in for the details), If you’ve been around the antibiotic ecosystem for a while, you’ve hopefully heard the story of the 2019 bankruptcy of Achaogen and the subsequent loss to the entire world of its
Dear All, Just in time for the United Nations General Assembly High-Level Meeting on AMR, the team behind the global burden of disease (GBD) estimates which we’ve discussed previously has released an excellent new report! Here are the links you need: The new report: “Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with
Dear All, Greetings from Porto (Portugal) where we’ve just ended the 2024 edition of the ESCMID-ASM Developer’s Meeting .. a superb congress with contributions from EMA, FDA, young investigators, older investigators, and points between. I enjoyed meeting so many of you this week! Three items today, all on the path to next week’s United Nations General Assembly High-Level
Dear All, The AMR HLM (High-Level Meeting) at the UN General Assembly starts at 10a ET today. You can watch it here on UN TV: https://webtv.un.org/en/asset/k11/k11knc6w2t Addendum: It’s available for replay at that same link. See also the 1 Oct 2024 newsletter for a review of the HLM. All best wishes, –jr John H. Rex, MD
Dear All (and with thanks to Kevin for co-authoring), Building on their excellent analysis of the value over 30 years (29 Nov 2022 newsletter) to the United States as well the value to the entire globe of a PASTEUR-style pull that creates 18 new qualifying antibiotics, Bonnifield and Towse have now released country-by-country analyses using the